Loading...
Market
How many new clinical trials for Wegovy will be announced by Dec 31, 2024?
2
Resolution / Starting Odds
0 • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%
ClinicalTrials.gov or official Novo Nordisk press release
Story
Novo Nordisk's Wegovy with Semaglutide Reduces Heart Failure and COVID-19 Risks by Up to 29%
Aug 30, 2024, 09:14 AM
Novo Nordisk's Wegovy, containing semaglutide, has been shown to reduce the risk of severe complications in patients with a common form of heart failure, according to a new analysis. Research indicates that semaglutide, found in both Ozempic and Wegovy, can decrease the risk of heart failure events and cardiovascular death by up to 29%. A study involving 3,533 diabetic patients highlighted a 27% lower risk of heart-related complications. Additionally, a Harvard study suggests that these medications also reduce the risk of severe COVID-19 in individuals with obesity. The SELECT trial further supports these findings, showing reduced COVID-19-associated morbidity and mortality.
View original story
Similar markets
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Significant increase (>10%) • 25%
Moderate increase (5-10%) • 25%
No significant change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Below 50,000 • 25%
50,000 to 100,000 • 25%
100,000 to 150,000 • 25%
Above 150,000 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
< 1 million • 33%
1 - 2 million • 33%
> 2 million • 34%
Yes • 50%
No • 50%
More than 5 trials • 25%
3 to 5 trials • 25%
1 to 2 trials • 25%
No new trials • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%
Exceeds expectations • 25%
Meets expectations • 25%
Falls short of expectations • 25%
Trial cancelled • 25%